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a b s t r a c t
Remarkable progress in structural biology has equipped virologists with insight into structures of viral
proteins and virions at increasingly high resolution. Structural information has been used extensively to
address fundamental questions about virtually all aspects of how viruses replicate in cells, interact with
the host, and in the design of antiviral compounds. However, many critical aspects of virology exist
outside the snapshots captured by traditional methods used to generate high-resolution structures. Like
all proteins, viral proteins are not static structures. The conformational ﬂexibility and dynamics of
proteins play a signiﬁcant role in protein–protein interactions, and in the structure and biology of virus
particles. This review will discuss the implications of the dynamics of viral proteins on the biology,
antigenicity, and immunogenicity of ﬂaviviruses.
Published by Elsevier Inc.
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An introduction to protein dynamics
It is well recognized that proteins exhibit liquid-like internal
motions and that many biological processes require substantial
plasticity in protein structure (reviewed by Karplus and Kuriyan,
2005). Protein motions span a large range in scale from picose-
cond–nanosecond motions localized to side chain and backbone
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dihedral rotations to longer timescale motions leading to internal
rearrangements of whole domains or polypeptide chains. Numer-
ous studies, both experimental and computational, have character-
ized small-amplitude, fast-timescale internal motions, and elucidated
the physical aspects and importance of localized ﬂuctuations to
protein function. Internal dynamics underlie induced-ﬁt ligand
binding, access to buried regions, and conﬁgurational entropy con-
tributions to protein energetics (Borbat et al., 2001; Dodson et al.,
2008; Kneller, 2005; Marsh et al., 2012; Osawa et al., 2012). By
contrast, relatively little is known about the larger amplitude motions
associated with conformational ﬂuctuations involving large segments
of polypeptide chains that deviate substantially from the equili-
brium/time-averaged structures deﬁned by crystallography or NMR
spectroscopy. Possibly the ﬁrst evidence of large amplitude excur-
sions from the average structure of a protein molecule comes from
hydrogen/deuterium exchange and pulsed proteolysis experiments;
the results indicate a transient accessibility of buried regions of the
polypeptide chain, described as a “local unfolding” event (Bai et al.,
1995; Park and Marqusee, 2004; Thomsen and Poulsen, 1993). Of
particular interest for this review are the proteins that comprise virus
particles, as both non-enveloped and enveloped viruses undergo
processes during the virus lifecycle that clearly require protein
dynamics and large amplitude internal motions. The change from
an immature to mature form of the virus, the entry into the host cell
through interaction with cellular membranes, and the uncoating and
release of the viral genome are all processes that involve large
changes in virus structure.
The conformational ﬂexibility of viral proteins
Viruses have evolved numerous strategies to deliver genetic
material from one host to another within viral capsids or virions.
Viruses balance a requirement to protect the viral genomewithin a
structure that is sufﬁciently stable to withstand potentially harsh
conditions experienced during transmission among cells and hosts
with a requirement to disassemble that same virus particle
following the infection of cells (reviewed by Mateu, 2013). The
viral proteins that orchestrate the entry of many enveloped viruses
into cells have been studied extensively and vary considerably in
structure (reviewed by Harrison, 2008). These proteins drive the
fusion of viral and cellular membranes that allows deposition of
viral cargo into target cells. Critical events in the entry process are
triggered by interactions with cellular macromolecules or envir-
onmental changes, and may exploit the conformational ﬂexibility
of viral proteins.
Entry of HIV-1 into cells is coordinated by a small number of
trimers of gp120 and gp41 proteins incorporated into the viral
membrane. This process has been studied extensively (reviewed
by Wilen et al., 2012; Wyatt and Sodroski, 1998), and is the target
of two classes of antiviral molecules used in the clinic (reviewed
by Haqqani and Tilton, 2013). Interactions between CD4 and HIV-1
catalyze changes in the structure of gp120 that result in the
formation of the binding site for viral co-receptors and the
displacement of variable loops that function to shield critical
surfaces of the viral entry machinery from the humoral response
(Kwong et al., 1998; Munro and Mothes, 2014; Wyatt et al., 1995).
Interactions between CD4-triggered gp120 and chemokine recep-
tors precede the large conformational changes in gp41 that drive
the formation of the energetically stable six-helix bundle and lipid
mixing (Pancera et al., 2014; Wyatt et al., 1995; Wyatt and
Sodroski, 1998). Of signiﬁcant interest, a recent study identiﬁed
three states of unliganded envelope trimers using single molecule
ﬂuorescence energy transfer (Munro et al., 2014). This exciting
study suggests the frequency with which gp120 populates each
state is modulated by receptor interactions. Thus an ensemble of
envelope trimer structures may contribute to the mechanics of
viral entry and sensitivity to neutralizing antibodies. While
incompletely understood, studies of monoclonal antibody (mAb)
reactivity suggest trimers of inﬂuenza HA also exist in multiple
states (Bachi et al., 1985).
Viral breathing: insights and concepts from the common cold
Despite the availability of elegant images of virions, they are not
static structures. Virions undergo large amplitude, concerted ﬂuctua-
tions at equilibrium, a phenomenon referred to as viral “breathing”
(Lewis et al., 1998). How breathing impacts viral structure and biology
is understood in the greatest detail for non-enveloped viruses
(reviewed by Mateu, 2013; Witz and Brown, 2001). Picornaviruses
are a family of small non-enveloped icosahedral viruses that cause a
variety of serious human illnesses, including poliomyelitis, meningitis,
and symptoms secondary to respiratory infections. Most picornavirus
capsids are composed of sixty copies each of four viral proteins
(VP1–VP4) (Racaniello, 2007). The exterior surface is formed by
VP1–VP3 proteins arranged with pseudo T¼3 symmetry (Fig. 1)
(Hogle et al., 1985; Rossmann et al., 1985). VP4 is internal in the virion
as demonstrated by X-ray crystallography and cryo-electron micro-
scopy. The ﬁve-fold symmetry axis of the virion of a sub-group of
picornaviruses features a canyon that contains amino acids involved in
binding the immunoglobulin-superfamily receptors used by many of
these viruses for attachment to target cells (Kolatkar et al., 1999; Olson
et al., 1993). Amino acids within the canyon are more conserved than
residues that form its rim and the surface of the virion. Because
antibody molecules may not efﬁciently access residues within the
canyon, regions involved in receptor recognition may be largely
unaffected by immune pressure (Rossmann and Palmenberg, 1988),
although exceptions have been noted (Smith et al., 1996). A hydro-
phobic pocket in VP1 beneath the ﬂoor of the canyon is occupied by a
“pocket factor” thought to promote particle stability (Hadﬁeld et al.,
1997). It is suggested that cellular receptors that bind the canyon
compete with pocket factor, which is likely a lipid, for binding to the
virion (Fig. 1) (Kolatkar et al., 1999). Thus, the displacement of pocket
factor reduces stability of the virion just prior to penetration of
target cells.
Structural changes of the picornavirus capsid drive penetration
into cells. Numerous cellular receptors for picornaviruses have
been identiﬁed. Many of these viruses bind receptors that interact
with the canyon. In these instances, interactions with receptor
result in the formation of an expanded, altered particle, or
A-particle, characterized by exposure of the VP1 amino-terminus
and a loss of the VP4 protein (Crowell and Philipson, 1971; Fricks
and Hogle, 1990). In this conﬁguration, the N-terminus of VP1,
which has a sequence corresponding to an amphipathic helix, is in
position to interact with cellular membranes. Subsequent injection
of the viral genome across the cellular membrane is triggered by
an unknown signal and is hypothesized to be facilitated by a
channel formed by rearranged VP1 and VP4 (Ren et al., 2013;
Strauss et al., 2013). Formation of the A-particle can occur
spontaneously in the absence of receptor, a process that can be
enhanced via incubation at higher temperature (Belnap et al.,
2000; Curry et al., 1996). Conversion to the A-particle in solution is
an irreversible ﬁrst order process at 37 1C that may be accelerated
17-fold in the presence of receptor (Carson, 2014). Despite
containing an intact positive-stranded RNA genome, the
A-particle is poorly infectious because it no longer binds efﬁciently
to receptor.
The breathing of picornaviruses has been inferred from several
types of experiments. Limited proteolysis studies of puriﬁed
poliovirus and human rhinovirus 14 identiﬁed exposure of the
otherwise internal VP4 protein and the amino terminus of VP1
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(Fricks and Hogle, 1990; Lewis et al., 1998). These protein regions
are located deep inside the capsid and, because the protease
cannot penetrate the protein boundary, it was reasoned that
large-scale concerted ﬂuctuations must occur in the native state
of the viral capsid to transiently expose them to the outside of the
capsid. Analogous results were observed for ﬂock house virus, a
non-enveloped particle with icosahedral symmetry that is classi-
ﬁed within the nodavirus family (Bothner et al., 1998). Neutralizing
antibodies are capable of trapping reversibly displayed structures
(Li et al., 1994; Roivainen et al., 1993); epitopes on these reversibly
exposed states are targets for antibody recognition following
infection (Jimenez-Clavero et al., 2000; Sauter et al., 2008). For
picornaviruses, viral breathing describes reversible transitions
between the “closed” state of the mature infectious virion, and
an “open” structure in which the amino-terminus of VP1 and VP4
are exposed. The open state of the virus particle may be uniquely
capable of binding receptor with high afﬁnity (McDermott et al.,
2000). In this context, the role of receptor may be to shift the
equilibrium towards the more open structure of the A-particle, as
discussed by Carson (2014) and Organtini et al. (2014).
Inhibiting viral breathing is an antiviral strategy
The signiﬁcance of capsid dynamics during the infectious cycle
of rhinoviruses is supported by the existence of antiviral com-
pounds that inhibit viral breathing. Several small molecule “WIN
compounds” (named for the Sterling Wintrop Research Institute)
have been developed that block infection by picornaviruses (Heinz
et al., 1989; Otto et al., 1985; Pevear et al., 1999; Turner et al.,
1993), and one has advanced to clinical trials with results yet to be
reported (NIH clinical trials identiﬁer: NCT00394914). These com-
pounds bind the same hydrophobic pocket beneath the canyon
ﬂoor as the pocket factor, inducing a local conformational change
(Fig. 1) (Pevear et al., 1989) and the entropic stabilization of the
capsid (Phelps and Post, 1995; Tsang et al., 2000). Viruses
Fig. 1. Structure of the picornavirus capsid and location of the hydrophobic pocket: The left panel shows a color-coded C-alpha backbone model of the basic repeating unit of
a picornavirus virion. The four capsid proteins, VP1–4 are color coded representing each of the proteins with VP4 being found on the interior of the particle apparently
protected from immune surveillance. 60 copies of this repeating unit are organized as an icosahedron (shown as the particle on the left). At each vertex, ﬁve copies of VP1
come together and create a depression or “canyon” where many receptors have been shown to bind. The right panel shows a ribbon diagram of a picornavirus VP1 capsid
protein showing the location of a small molecule inhibitor binding into the hydrophobic pocket normally occupied by pocket factor. The binding site is underneath the
canyon ﬂoor and binding of inhibitor limits the ﬂexibility and dynamics of the particle.
Fig. 2. The structure, arrangement, and dynamic motion of E proteins on the mature ﬂavivirus virion: (A) Top view of the ﬂavivirus E protein monomer shown as a ribbon
diagram, with domains I–III (DI–DIII) colored in red, yellow, and blue, respectively. The conserved fusion loop at the distal tip of domain II (DII-FL) is colored in green. Not
shown are the helical stem and transmembrane anchor located at the carboxy terminus of DIII. (B) The surface of the mature virion contains 90 sets of head-to-tail E protein
dimers arranged with pseudo T¼3 icosahedral symmetry. Domains are colored as in panel A. The ﬂavivirus virion must strike a balance between protection of the RNA
genome during transmission and the ability to disassemble the virus structure during the entry process. The strength of the contacts between E proteins that hold together
the virion structure may differ among viral strains due to sequence variation, with the potential to increase or decrease the extent of conformational ﬂexibility. The effects of
this may be relevant in terms of amino acid contacts (B) between E protein rafts, (C) between the E homodimers that comprise the rafts, (D) at the E dimer interface, and
(E) at the level of an individual E protein.
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incubated with WIN compounds do not transiently display the
otherwise internal N-termini of VP1 and VP4 characteristic of
capsids that breathe at equilibrium, indicating that WIN binding
dampens the large-amplitude capsid ﬂuctuations (Lewis et al.,
1998; Reisdorph et al., 2003). Stabilization of picornavirus capsids
has the potential to inhibit infection via several mechanisms. WIN
compounds interfere with interactions of rhinoviruses that use
ICAM-1 receptors that bind within the canyon (Pevear et al., 1989).
However, as not all picornaviruses bind the same receptors nor do
so via similar viral structures, blocking attachment is not a
universal mode of antiviral action (Hewat et al., 2000). More
generally, the stabilization conferred by WIN-compound binding
prevents the loss of VP4 that occurs during the viral uncoating
process described above (Gruenberger et al., 1991; Heinz et al.,
1989; McSharry et al., 1979). Thus the dampened motions of the
native viral capsid in the presence of WIN compounds are
consistent with these motions contributing to cell entry and
uncoating. Beyond their potential utility as therapeutics, com-
pounds that block viral breathing of picornaviruses have proven to
be powerful tools for investigating the dynamics of viral proteins
and the ensemble of structures sampled by viruses at different
stages of the viral entry pathway (Roy and Post, 2012).
Flaviviruses
Flaviviruses are a large group of RNA viruses transmitted princi-
pally by arthropod vectors. Viruses within this group are responsible
for considerable morbidity worldwide. For example, it is estimated
that roughly 390 million dengue virus (DENV) infections occur each
year, and one third of the human population is at risk of infection
(Bhatt et al., 2013). Flaviviruses are spherical, enveloped virions
composed of three structural proteins (reviewed by Mukhopadhyay
et al., 2005). The capsid protein is a small, alpha-helical molecule
found within virions that interacts with lipids and the positive-
stranded viral RNA genome (Ma et al., 2004). The capsid-RNA
complex within the virus particle appears unstructured (Kuhn et
al., 2002). The premembrane (prM) protein functions as a chaperone
for the envelope (E) protein. prM binds E shortly after synthesis,
facilitates protein folding, and is incorporated into the virus particle
in complex with the E protein (Konishi and Mason, 1993; Lorenz et
al., 2002). The E protein is an elongated class II viral membrane
fusion protein that orchestrates viral assembly, budding, and entry
into target cells. It is also the principal target of neutralizing
antibodies (reviewed by Diamond et al., 2008; Dowd and Pierson,
2011).
The E protein is comprised of three domains connected by short
ﬂexible linkers (Fig. 2A) (Kanai et al., 2006; Luca et al., 2012; Modis et
al., 2003). This elongated molecule is anchored to the viral membrane
by a helical stem and two antiparallel transmembrane domains. E
protein domain III (E-DIII) is an immunoglobulin-fold that, in some
laboratory-adapted strains, contains sites of interactions with nega-
tively charged heparin sulfate molecules on target cells (Chen et al.,
1997). E-DIII contains epitopes recognized by potently neutralizing
antibodies (Beasley and Barrett, 2002; Crill and Roehrig, 2001;
Gromowski and Barrett, 2007; Oliphant et al., 2005; Sanchez et al.,
2005; Shrestha et al., 2010), although the contribution of antibodies of
these speciﬁcities in vivo is questionable (Wahala et al., 2012, 2009;
Williams et al., 2012). Domain II (E-DII) is a long ﬁnger-like domain
containing residues involved in the formation of the antiparallel
dimers present on mature viruses. A highly conserved fusion loop
(DII-FL) is located at the distal end of this domain; the majority of
antibodies that bind the DII-FL are cross-reactive and vary consider-
ably in neutralization potency (Nelson et al., 2008; Oliphant et al.,
2006; Stiasny et al., 2006). E-DI is a beta barrel structure positioned
between DIII and DII. Depending on the viral species and strain, the E
protein may contain asparagine-linked sugars on DI and DII. One
essential role of the E protein is to catalyze fusion between viral and
cellular membranes in the acidic environment of the endosome
(reviewed by Pierson and Kielian, 2013). Under these low pH condi-
tions the E protein homodimers rearrange into fusion-competent E
protein homotrimers. This rearrangement is accomplished by con-
siderable movement among the three E protein domains made
possible by the hinges that connect them. This ﬂexibility is reﬂected
by differences in the intra-domain angles captured by the numerous E
protein structures now available (Bressanelli et al., 2004; Luca et al.,
2012; Modis et al., 2003, 2004; Zhang et al., 2004). Of interest, recent
studies suggest that some antibodies recognize epitopes not captured
by soluble E proteins, indicative of quaternary epitopes expressed only
in the context of the intact virion (Beltramello et al., 2010; de Alwis
et al., 2012; Kaufmann et al., 2010).
Flaviviruses assemble at membranes of the endoplasmic reticulum
as non-infectious immature viruses. prM and E proteins are present on
immature virions as an icosahedral array of spikes composed of three
prM–E heterodimers (Zhang et al., 2007). In this arrangement, prM is
positioned close to the DII-FL and prevents adventitious fusion of the
virus during egress (Guirakhoo et al., 1991; Yu et al., 2009). While
immature viruses are incapable of fusion (Elshuber et al., 2003), the
presence of prM does not lock E proteins of the virus into a single
conﬁguration. Exposure of spikey immature virions to an acidic
environment during egress results in a reorganization of prM and E
that orients E proteins roughly ﬂat against the surface of the virion as
homodimers, and reveals a cleavage site on prM recognized by furin-
like proteases (Yu et al., 2008). Cleavage of prM by furin is required for
the formation of infectious virions, but can be incomplete (Cherrier
et al., 2009; Zhang et al., 2007). The result of this virion maturation
process is a membrane-anchored M peptide, and a soluble “pr”
molecule that remains associated with the virus particle until it is
released into the neutral pH of the extracellular space. The mature
virus is a relatively smooth virion on which E proteins are arranged in
rafts of three antiparallel dimers (Kuhn et al., 2002; Mukhopadhyay
et al., 2003).
Structural heterogeneity arising from incomplete prM cleavage
Flaviviruses are secreted from cells as a structurally hetero-
geneous population of virus particles that retain uncleaved prM
protein in varying amounts (reviewed by Pierson and Diamond,
2012). Partially mature viruses are deﬁned herein as prMþ virions
with less than 180 copies of uncleaved prM. Because the amount of
uncleaved prM retained on ﬂaviviruses differs by virus, is inﬂu-
enced by viral sequence diversity, and is impacted by the cell line
in which virions are produced, the structures of partially mature
virions are expected to vary (Junjhon et al., 2010). Cryo-electron
tomographic analysis of partially mature viruses identiﬁed a
mosaic structure of discrete regions of mature-like and
immature-like structure (Plevka et al., 2011). The prM content of
virions has been shown to markedly impact sensitivity to neu-
tralization by many classes of antibodies (Oliphant et al., 2006;
Pierson et al., 2007) and some polyclonal mixtures of antibody
elicited by candidate ﬂavivirus vaccines (Nelson et al., 2008).
Because the process of virion maturation is irreversible, changes
in the structure or antigenic surface of the virion after release
must be attributed to other processes.
Structural hints of a dynamic virion
While biological processes cannot be inferred solely from static
structures, interest in the dynamics of ﬂaviviruses arose from the
cryo-electron reconstruction of DENV serotype 2 (DENV2) with
Fab fragments of a cross-reactive DENV antibody. 1A1D-2 is a murine
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mAb capable of potently neutralizing DENV serotypes 1–3, but not 4
(Lok et al., 2008). This mAb binds an epitope that includes the
β-strand of DIII, which is not predicted to be accessible for binding on
the mature virus particle. Interestingly, efﬁcient binding of 1A1D-2
Fab fragments to the virion was achieved at 37 1C, but not 4 1C.
Reconstruction studies of the virus–Fab complex revealed that an
unexpected degree of structural change in DENV was required for
binding. These ﬁndings suggest 1A1D-2 trapped a temperature-
dependent conformation of the virus on which the otherwise cryptic
DIII β-strand epitope was accessible.
Two recent follow-up studies of DENV structure at 37 1C in the
absence of antibody suggest the structure of the virus particle
changes at physiological temperatures (Fibriansah et al., 2013;
Zhang et al., 2013). Exposure of DENV2 to 36 1C or 37 1C results in
the rapid (within minutes) formation of an extended “bumpy”
structure. The structure of DENV2 in this conﬁguration is a more
open conformation created by the rotation of E protein dimers
outward, creating greater access to the viral lipid membrane.
Incubation of DENV2 at physiological temperatures was also
associated with a marked increase in the heterogeneity of the
virus population. While interpreting these ﬁndings against the
backdrop of the modest particle-to-infectious particle ratio of
ﬂaviviruses is challenging, it is clear that changes in temperature
have the potential to alter the structure(s) of DENV in ways that
could impact the biology of the virion. Because “bumpy” particles
have not been observed for all DENV serotypes studied
(Kostyuchenko et al., 2014), future studies are required to identify
viral features responsible for temperature-dependent changes in
structure.
The dynamics of ﬂaviviruses
The dynamic properties of ﬂaviviruses have been inferred
principally from analyses of antibody reactivity. Epitope mapping
studies have been completed for large panels of human and
murine antibodies (de Alwis et al., 2012; Oliphant et al., 2007;
Shrestha et al., 2010; Sukupolvi-Petty et al., 2010; Throsby et al.,
2006). The utility of static models of ﬂavivirus structure for
translating this information into a detailed understanding of the
molecular basis of viral recognition has been limited. Epitopes
recognized by many mAbs with neutralizing activity are located on
surfaces of the E protein not expected to be displayed on the
surface of the virus particle (cryptic epitopes), or are occluded by
the close proximity of neighboring E proteins (Austin et al., 2012;
Lok et al., 2008; Nybakken et al., 2005; Oliphant et al., 2006;
Stiasny et al., 2006). For example, the neutralizing DENV mAb E111
binds DIII on its lateral face roughly along the plane of the viral
membrane. It is difﬁcult to imagine how an intact antibody could
access this structure on a static virus particle (Austin et al., 2012).
Epitopes may also be displayed in a non-equivalent fashion among
the 180 E proteins that comprise the virion. mAb E16 is a West Nile
virus (WNV)-speciﬁc potently neutralizing antibody capable of
binding only two thirds of the E-DIII lateral ridge (DIII-LR) epitopes
on the mature virion. DIII-LR epitopes located adjacent to the ﬁve-
fold symmetry axis are not bound by E16 due to steric constraints
(Kaufmann et al., 2006; Nybakken et al., 2005). Not all epitopes are
equally accessible for antibody binding; epitope accessibility is a
principal factor that deﬁnes the potency of neutralizing antibodies
(reviewed by Dowd and Pierson, 2011).
The conformational ﬂexibility of ﬂaviviruses has the potential
to impact sensitivity to antibody-mediated neutralization through
changes in epitope accessibility (Fig. 3). Thus, antibodies are a
powerful tool to probe the structure(s) of infectious ﬂavivirus
virions. The DII-FL epitope of WNV is not predicted to be accessible
for antibody recognition on the mature virion. The neutralization
potency of the DII-FL-reactive mAb E53 is very sensitive to the
maturation state of the virion: both functional and structural
studies suggest this antibody cannot bind the mature virion
because its epitope is non-accessible (Cherrier et al., 2009;
Nelson et al., 2008). Incubation of E53 with preparations of mature
WNV under conditions sufﬁcient to achieve steady-state binding
Fig. 3. Flavivirus dynamics results in reversible and non-reversible conformational changes: ﬂavivirus neutralization is governed by a stoichiometric threshold and requires
binding by a critical number of antibody molecules per virion. Of the 180 potential E protein epitopes (x-axis, bottom of ﬁgure), estimates suggest that the neutralization
threshold corresponds to docking on the virion by 30 antibodies (Pierson et al., 2007). In addition to antibody afﬁnity, epitope accessibility is a critical factor that determines
whether neutralization occurs. Because of the dense arrangement of E proteins on the surface of the mature virion, not all E protein epitopes are equally accessible for
antibody binding. For some characterized antibodies, neutralization cannot be achieved even in the presence of saturating concentrations of antibody due to the lack of
accessible epitopes (Nelson et al., 2008). Flavivirus dynamics can modulate the landscape available for antibody binding by transiently exposing otherwise inaccessible
epitopes and increasing the absolute number available for binding. Time- and temperature-dependent increases in neutralization are observed when virus and antibody are
incubated for increasing lengths of time (left panel; Ref¼reference curve obtained after pre-incubation of virus with serial dilutions of antibody for 1 h; additional antibody-
virus complexes were further incubated at 37 1C for 5–26 h before infecting target cells). This particular antibody binds an epitope shown to be inaccessible on the mature
form of the virus. Time-dependent increases in neutralization potency reﬂect exposure of this otherwise “cryptic” epitope through the process of virus breathing. In addition
to reversible changes in virus structure (green arrows), we hypothesize that a subset of conformational transitions sample non-infectious structures that can no longer return
to an infectious state (red arrow). These “dead-end” structures are detected experimentally as a loss of virus infectivity over time in solution, referred to as intrinsic decay.
Differences in the rate of intrinsic decay (shown for WNV and DENV, right panel) among virus strains indicate that sequence variation dictates the steady state virus
structures and/or the ensembles available for virus breathing.
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resulted in very little inhibition of infection. However, prolonged
incubation of WNV in the presence of antibody resulted in marked
increases in the neutralization activity of E53 (Dowd et al., 2011).
Because the E53 epitope is not displayed on the mature virion, time-
and temperature-dependent increases in neutralization are thought to
reﬂect changes in presentation of an otherwise structurally inacces-
sible epitope on mature viruses. Increased neutralization sensitivity
may reﬂect a change in the number of epitopes available for recogni-
tion and/or changes in structure that allow for higher afﬁnity or
potentially bivalent binding. Time- and temperature-dependent pat-
terns of neutralization are a characteristic of all anti-ﬂavivirus E
protein antibodies tested to date (Austin et al., 2012; Dowd et al.,
2011, 2014; Sabo et al., 2012). The magnitude of the shift in
neutralization potency among ﬂavivirus antibodies correlates generally
with the predicted accessibility of an epitope on the mature virus. For
example, prolonged incubation of E16, which binds the relatively
accessible DIII lateral ridge epitope results in just a few-fold increase in
neutralization, whereas other antibodies that bind cryptic determi-
nants become more than 100-fold more potent. Importantly, the
extent to which neutralization sensitivity can be increased by pro-
longed incubation is ﬁnite; once all epitopes are engaged by antibody,
further incubation would not be expected to impact antibody potency
(Dowd et al., 2011, 2014).
As introduced above, the accessibility of many epitopes is
modulated by the maturation state of the virus particle. The process
of virion maturation reduces the potency of many neutralizing
antibodies because epitopes become less accessible on the dense
array of E proteins that comprise the mature virion. In contrast,
prMþ partially mature viruses are generally more sensitive to
neutralization (Dowd et al., 2014; Nelson et al., 2008). Recent studies
demonstrate that both mature and prMþ virions are dynamic
structures. Time-dependent changes in antibody potency were
observed in studies of populations of WNV or DENV produced in a
manner that allows the extent of prM cleavage to be controlled
(Dowd et al., 2014). Of interest, even very long incubations of mature
virus with antibody were not sufﬁcient to render these virions as
sensitive to neutralization as prMþ immature-like virus particles.
The rapid on-rate of antibodies provides a means to bind and trap
transiently exposed regions otherwise buried in the equilibrium
structure. Viral breathing in the presence of neutralizing antibodies
has the potential to display an epitope for recognition, which in turn
provides a mechanism to contribute to the stoichiometry required for
virus neutralization (Pierson et al., 2007). Neutralization studies of
picornaviruses suggest the VP4 protein is exposed via reversible
processes on dynamic, breathing virus particles. Likewise, structural
transitions that expose epitopes on infectious mature ﬂaviviruses also
appear to be reversible. Time-dependent changes in sensitivity to
neutralization by antibodies that recognize poorly accessible epitopes
required the presence of antibody during the prolonged incubation.
Prolonged incubation in the absence of antibody resulted in neutra-
lization titers similar to those of the conventional neutralization
assays run in parallel (Dowd et al., 2014). The impact of viral
breathing on the neutralization potency of antibodies does not
require extended incubation in all circumstances. mAb E111 is a
potent DENV type-speciﬁc mAb that binds an epitope on DIII not
predicted to be exposed on mature or immature forms of the virion
(Austin et al., 2012). The accessibility of this epitope reﬂects the
dynamic properties of the virion, which have been reported to vary
among DENV strains (Austin et al., 2012; Sukupolvi-Petty et al., 2013).
Thus, relationships between neutralization potency and the predicted
accessibility of epitopes on ﬂaviviruses require a deeper understand-
ing of factors that govern the ensemble of structures that exist at
steady state under physiologically-relevant conditions.
Alternatively, beyond revealing otherwise buried antibody
epitopes, the conformational dynamics of the virus particle may
play an important role in the formation of complex quaternary
epitopes on the surface of the mature virus particle. Several recent
studies have identiﬁed mAbs that appear to bind the virus particle,
but not soluble E proteins. Antibody mapping and structural
studies of WNV and DENV identify a class of epitopes composed
of residues found on multiple E proteins (de Alwis et al., 2012;
Dejnirattisai et al., 2015; Fibriansah et al., 2014; Fibriansah et al.,
2015; Kaufmann et al., 2010; Rouvinski et al., 2015; Teoh et al.,
2012). For example, a recent class of mAbs has been described that
bind E dimer-dependent epitopes (EDE), resulting in potent
neutralization of all four serotypes of DENV. A similar pattern of
reactivity was recently described in serologic studies of tick-borne
encephalitis virus infection and vaccination (Jarmer et al., 2014;
Kiermayr et al., 2009). This EDE epitope includes multiple features
of the dimer interface including the conserved DII-FL, and overlaps
the portion of E bound by prM on immature or partially mature
DENV virions (Rouvinski et al., 2015). Of signiﬁcant interest, EDE
mAbs are equally potent when uncleaved prM is retained on the
virion (Dejnirattisai et al., 2015). These ﬁndings raise the possibi-
lity that E protein dimers and trimers exist as a dynamic equili-
brium between these oligomeric states. The displacement of prM
by EDE antibodies is thought to stabilize the surface-accessible
dimer-interface epitope, trapping the virus particle in a mature
conformation.
Intrinsic decay
Like many viruses, the prolonged incubation of ﬂaviviruses at
physiological temperatures results in a loss of infectivity (Fig. 3)
(Ansarah-Sobrinho et al., 2008; Dowd et al., 2014). This process is
referred to herein as intrinsic decay. Practical considerations have
prompted studies to deﬁne conditions to enhance the half-life of
infectious virions (Wiggan et al., 2011). However, insights into why
ﬂaviviruses become non-infectious in solution have not been
reported. We hypothesize that the intrinsic decay of ﬂaviviruses is
a characteristic of a dynamic virus particle. From this perspective, it is
possible that not all structural pathways sampled by the virus (or its
E proteins) at equilibrium will be reversible, and these in turn may
not be compatible with virus attachment or entry. The intrinsic decay
rate for WNV and DENV differ signiﬁcantly, as does the rate with
which these viruses become more sensitive to neutralization when
incubated with antibody for prolonged periods (Dowd et al., 2014).
Furthermore, in recent studies, E protein variants found to alter the
neutralization potency of mAbs at a distance (outside the epitope)
also modulate intrinsic decay (Dowd and Pierson, unpublished data).
The structural basis for intrinsic decay is not known. While it is
attractive to imagine that ﬂaviviruses adopt a non-infectious struc-
ture equivalent to the A-particle of picornaviruses, this may be
difﬁcult to support experimentally. Flaviviruses are structurally
heterogeneous due to the presence of uncleaved prM protein, and
may be infectious depending upon the efﬁciency of virion maturation
(reviewed by Pierson and Diamond, 2012). Recent studies suggest
they may rapidly become more structurally heterogeneous upon
incubation at physiological temperatures (Fibriansah et al., 2013;
Zhang et al., 2013). Identifying a non-infectious virion among a
heterogeneous population by virtue of its structure is not possible.
Unanswered questions
The dynamics of non-enveloped viruses has been studied using
numerous techniques and exploited for the development of anti-
virals. In contrast, very little is understood about the breathing of
enveloped virions. When considered in the context of the ﬂavi-
virus replication cycle, numerous questions remain, including:
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What interactions control the dynamics of the virion?
The structure of ﬂaviviruses changes markedly during the
maturation process of virions. As immature virus particles, E proteins
exist as trimers in complex with prM. E proteins are present on
mature viruses as anti-parallel dimers; the surface of the virus is
composed of “rafts” of three dimers (Fig. 2B) (Kuhn et al., 2002). Both
immature and mature forms of the virion appear to sample multiple
conformations at physiological temperatures (Dowd et al., 2014). The
molecular interactions that govern the ensemble of structures
sampled by each form of the virion are unknown. On mature virions,
the conformational ﬂexibility of E proteins may be a key feature of a
dynamic virus particle (Fig. 2B–E). The linkers connecting the three
domains of each E protein monomer confer an ability to rotate that
enable the conformational changes that drive fusion during viral
entry (Fig. 2E) (reviewed by Pierson and Kielian, 2013). Local motion
of the E protein on the mature virus particle may be sufﬁcient to
expose otherwise cryptic neutralizing antibody epitopes and may be
required for the virus to sample its environment in its search to bind
and enter cells efﬁciently. However, this in turn may bemodulated by
the strength of interactions that maintain the E protein dimers that
comprise the mature virion (Fig. 2D). Of signiﬁcant interest, Luca and
colleagues hypothesized that the contribution of E protein dimers to
the overall stability of the virion may vary among ﬂaviviruses,
consistent with differences in intrinsic decay (Luca et al., 2012). The
interface that mediates E protein dimers is not of uniform size among
ﬂaviviruses. For example, structural features that contribute to tick-
borne encephalitis virus (TBEV) dimers do not exist at the interface of
Japanese encephalitis virus (JEV) E protein dimers. The conclusion
that E protein dimers of viruses of the JEV serocomplex are of lower
afﬁnity is supported by the observation that their E proteins are
monomers in solution, as compared to the dimers of DENV and tick-
borne encephalitis viruses (Luca et al., 2012). This raises the yet
unexplored possibility that stability of JEV serocomplex viruses may
instead be governed by interactions among dimers on the mature
virion. Finally, E protein contacts also orchestrate in the herringbone
arrangement of E protein rafts on the surface of the mature virion,
providing another potential avenue for modulating virion stability
(Fig. 2B and C).
How does sequence diversity among viruses impact dynamics?
Recent ﬁndings suggest sequence variation among ﬂaviviruses
has the potential to shape the structural ensemble of the virus
particle. The potency of the DENV1-reactive mAb E111 varies
signiﬁcantly among related strains (Shrestha et al., 2010). Struc-
tural and functional studies demonstrated that sequence variation
within the E111 DIII epitope could not explain genotypic differ-
ences in the sensitivity of DENV1 strains Western Paciﬁc and
16007 to neutralization (Austin et al., 2012). Because this epitope
is predicted to be inaccessible on the mature virion, a role for
dynamics was hypothesized and supported by the observation
that time- and temperature-dependent patterns of neutralization
sensitivity differed for these viruses. Exposure of the Western
Paciﬁc strain to elevated temperatures resulted in rapid changes in
neutralization sensitivity of signiﬁcant magnitude, whereas paral-
lel studies with 16007 revealed only modest changes (Austin
et al., 2012). The precise determinants of E111 sensitivity are
currently being investigated. The identiﬁcation and characteriza-
tion of mutations in WNV or DENV that alter both intrinsic decay
and kinetic patterns of neutralization will be instructive.
An impact of viral sequence diversity on the dynamics of
virions has been studied previously. Adeno-associated virus
(AAV) is a non-enveloped, single-stranded DNA virus with a T¼1
icosahedral capsid. AAV exists as at least thirteen serotypes
(reviewed by Wu et al., 2006). Recent biophysical studies of the
dynamics of AAV capsids discovered strain-dependent differences
in the behavior of AAV in solution (Rayaprolu et al., 2013). Using
multiple approaches, Rayaprolu and colleagues identiﬁed large
differences in the thermal stability of AAV in solution that did not
correlate with the overall sequence divergence among the repre-
sentative strains analyzed. While limited proteolysis studies sug-
gested the capsids of all AAV are characterized by conformational
ﬂexibility, the patterns of cleavage sensitivity varied among the
viruses studied.
Are dynamics something to be considered in the context of ﬂavivirus
vaccine design?
Many epitopes recognized by neutralizing antibodies are poorly
accessible on the mature ﬂavivirus particle and are exposed for
recognition only on breathing virus particles or on those that
retain uncleaved prM protein. Whether structural heterogeneity is
a beneﬁcial property of immunogens or live-attenuated virus
vaccines has not been evaluated. Would more dynamic immuno-
gens elicit more potent cross-reactive antibody responses? Alter-
natively, might enhanced exposure of otherwise cryptic epitopes
prime a response that targets epitopes available for antibody
binding only at low occupancy? Antibodies with these character-
istics have been hypothesized to contribute to enhanced disease
following secondary DENV infections (Halstead, 2003; Kliks et al.,
1988). Modulating the dynamic characteristics of live-attenuated
vaccine candidates has the potential to enrich for more desirable
antibody responses. Future studies that identify and characterize
the underlying mechanisms behind ﬂavivirus breathing and the
speciﬁc amino acids or protein structures involved in dynamics
will guide these exciting new prospects.
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